MARKET INSIGHTS
Global cardiovascular and cerebrovascular Chinese patent medicine market size was valued at USD 10.49 billion in 2024. The market is projected to grow from USD 11.28 billion in 2025 to USD 18.76 billion by 2032, exhibiting a CAGR of 8.9% during the forecast period.
Cardiovascular and cerebrovascular Chinese patent medicines are traditional herbal formulations used for treating conditions like coronary heart disease, stroke, hypertension, and arrhythmias. These medicines come in various forms including oral preparations (tablets, capsules) and injections, combining centuries-old herbal wisdom with modern pharmaceutical standards.
The market growth is driven by increasing cardiovascular disease prevalence globally, with WHO reporting approximately 17.9 million CVD deaths annually. China dominates production and consumption, benefiting from government support for traditional medicine integration into healthcare systems. However, stringent regulatory hurdles in western markets and competition from conventional pharmaceuticals present challenges. Key players like Tasly Pharmaceutical and Beijing Tongrentang continue expanding through R&D investments and international collaborations.
MARKET DYNAMICS
MARKET DRIVERS
Rising Global Burden of Cardiovascular Diseases Accelerates Market Growth
The cardiovascular and cerebrovascular Chinese patent medicine market is experiencing substantial growth due to the escalating global prevalence of cardiovascular diseases. Recent data indicates that cardiovascular diseases account for nearly 32% of all global deaths annually, with cerebrovascular conditions like stroke representing a significant portion of disease burden. This growing patient population creates sustained demand for effective Traditional Chinese Medicine (TCM) formulations that offer holistic treatment approaches with fewer side effects compared to Western pharmaceuticals.
Government Support for TCM Integration Boosts Market Expansion
China's robust policy support for traditional medicine integration into mainstream healthcare continues to drive market growth. The "Healthy China 2030" initiative specifically promotes the development and standardization of TCM, with cardiovascular formulations being a priority area. Regulatory reforms have streamlined approval processes for patent medicines while maintaining rigorous quality control standards. This supportive policy environment has enabled leading manufacturers like Tasly Pharmaceutical and Beijing Tongrentang to accelerate R&D and expand production capacities.
Furthermore, increasing insurance coverage for Chinese patent medicines in both public and private healthcare systems enhances affordability and access. In major provincial health insurance catalogs, reimbursement rates for critical cardiovascular TCM formulations now exceed 70% of treatment costs, significantly lowering patient out-of-pocket expenses.
MARKET RESTRAINTS
Stringent International Regulatory Barriers Limit Global Expansion
Despite strong domestic growth, the cardiovascular and cerebrovascular Chinese patent medicine market faces significant challenges in global markets. Western regulatory agencies often require extensive clinical trial data that differs from traditional TCM efficacy evaluation methods. The average approval process for a Chinese patent medicine in European or North American markets can take 5-8 years longer than domestic China approvals, creating substantial market entry barriers.
Standardization Challenges Impact Product Quality Consistency
The inherent variability in herbal ingredients presents ongoing quality control challenges for manufacturers. Unlike synthetic pharmaceuticals, natural product formulations must account for variations in growing conditions, harvest times, and processing methods that can affect active compound concentrations. Recent quality audits reveal that up to 15% of batch samples may fall outside pharmacopeia specifications for certain marker compounds. This variability complicates large-scale production while increasing compliance costs for manufacturers pursuing international markets.
MARKET OPPORTUNITIES
Growing Acceptance of Integrative Medicine Creates New Market Potential
The increasing global acceptance of integrative medicine approaches presents significant growth opportunities. Major healthcare systems in Europe and North America are increasingly incorporating TCM modalities, with cardiovascular health being a primary application area. Leading manufacturers are responding by developing standardized extract formulations that meet international good manufacturing practice (GMP) standards while preserving traditional therapeutic principles.
Digital Health Integration Opens New Distribution Channels
The rapid digitization of healthcare creates opportunities for innovative distribution models. Leading companies are leveraging e-commerce platforms and telemedicine partnerships to reach new patient populations. Online sales of cardiovascular TCM products grew by 42% year-over-year in 2023, demonstrating strong consumer adoption of digital health solutions. Smart packaging technologies with QR code authentication further enhance product traceability and patient engagement.
MARKET CHALLENGES
Patent Protection Issues Constrain Innovation
The traditional nature of many cardiovascular TCM formulations creates intellectual property protection challenges. Unlike novel chemical entities, traditional formulas often cannot be patented, leading to widespread generic competition. This limits R&D returns for companies developing improved formulations. Recent cases show that 60% of new TCM cardiovascular product launches face generic competition within 2 years in China.
Supply Chain Vulnerabilities Impact Raw Material Availability
Fluctuations in herbal supply chains present ongoing operational challenges. Climate change effects on key medicinal plant cultivation, coupled with increasing global demand for select herbs, have led to periodic shortages. Prices for premium-grade Danshen (Salvia miltiorrhiza), a critical ingredient in cardiovascular formulations, have increased by 35% since 2020, putting pressure on manufacturer margins. Vertical integration strategies and sustainable cultivation partnerships are becoming essential mitigation approaches.
Segment Analysis:
By Type
Oral Formulations Lead the Market Due to Patient Preference and Convenience Factors
The market is segmented based on type into:
-
Oral
-
Injection
-
Topical
-
Others
By Application
Hospital Segment Dominates with Comprehensive Treatment Capabilities
The market is segmented based on application into:
Hospital
Pharmacy
Clinic
Home Care
Others
By Indication
Coronary Heart Disease Segment Holds Significant Market Share
The market is segmented based on indication into:
Coronary Heart Disease
Hypertension
Cerebral Apoplexy
Arrhythmia
Others
COMPETITIVE LANDSCAPE
Key Industry Players
Domestic Giants Battle with International Firms in Expanding Traditional Medicine Market
The cardiovascular and cerebrovascular Chinese patent medicine market exhibits a moderately fragmented competitive landscape, featuring a mix of century-old traditional Chinese medicine (TCM) manufacturers and modern pharmaceutical companies. Beijing Tongrentang, established in 1669, dominates the market with its extensive distribution network and comprehensive product portfolio covering both oral and injectable formulations. The company controls approximately 18% of the domestic market share as of 2024.
Tasly Pharmaceutical and Shineway Pharmaceutical have emerged as formidable competitors through strategic modernization initiatives. Tasly's Compound Danshen Dripping Pill, one of China's first TCM products to undergo FDA clinical trials, exemplifies the industry's push toward international standardization. Meanwhile, Shineway has gained significant traction through its focus on evidence-based TCM research and hospital channel penetration.
The market has witnessed increased competition from international players like Dr. Willmar Schwabe GmbH & Co. KG, which combines Western phytopharmaceutical expertise with TCM principles. Their expansion into Asia-Pacific markets through joint ventures demonstrates the growing global interest in cardiovascular herbal medicines.
Two distinct competitive strategies are emerging: traditional manufacturers are investing heavily in clinical validation and quality control to meet international standards, while modern pharmaceutical firms are acquiring TCM brands to diversify their portfolios. This dynamic has led to several strategic acquisitions, including Sinopharm Group's consolidation of multiple regional TCM producers.
List of Key Cardiovascular and Cerebrovascular Chinese Patent Medicine Companies (2024)
-
Beijing Tongrentang (China)
-
Tasly Pharmaceutical (China)
-
Shaanxi Buchang Pharmaceutical (China)
-
Hutchison Whampoa Guangzhou Baiyunshan Chinese Medicine Company Limited (China)
-
Dr. Willmar Schwabe GmbH & Co. KG (Germany)
-
Shanxi Guang Yu Yuan Limited Company of Chinese Medicine (China)
-
KPC Pharmaceuticals (China)
-
Sinopharm Zhijun (China)
-
Shijiazhuang Yiling Pharmaceutical (China)
-
Shanxi Liye Pharmaceutical (China)
-
Shineway Pharmaceutical (China)
-
Guangzhou Baiyunshan Xingqun Pharmaceutical (China)
-
Jilin Xingxing Technology Pharmaceutical (China)
-
Sinopharm Zhonglian Pharmaceutical (China)
CARDIOVASCULAR AND CEREBROVASCULAR CHINESE PATENT MEDICINE MARKET TRENDS
Integration of Traditional Chinese Medicine with Modern Healthcare to Drive Market Growth
The growing recognition of traditional Chinese medicine (TCM) in global healthcare systems is significantly boosting demand for cardiovascular and cerebrovascular patent medicines. These formulations, developed using centuries-old herbal knowledge combined with modern pharmaceutical techniques, are gaining traction as complementary therapies. With an expanding evidence base, key products like Danshen Dripping Pills and Tongxinluo Capsules demonstrate clinically validated efficacy in improving microcirculation and reducing cardiac ischemia. The market benefits from increasing government support in China, where TCM accounts for approximately 40% of total pharmaceutical sales in the domestic cardiovascular segment. Meanwhile, international acceptance grows as regulatory bodies like the FDA and EMA approve select TCM-derived ingredients for adjunctive treatment protocols.
Other Trends
Prevention-Focused Healthcare Models
The shift toward preventive healthcare in aging populations creates strong demand for maintenance-dose TCM formulations. Unlike Western drugs that primarily target acute symptoms, Chinese patent medicines are increasingly prescribed for long-term vascular system maintenance, with clinical studies showing 20-30% reduction in stroke recurrence rates among compliant patients. This prophylactic application significantly expands the addressable market beyond diagnosed patients to high-risk populations, particularly in Asia-Pacific regions where population aging rates exceed 3% annually. Packaging innovations facilitating convenient daily dosing further support this trend toward preventive use.
Technological Advancements in Formulation Development
Modern extraction and quality control technologies are revolutionizing TCM production, allowing manufacturers to achieve pharmaceutical-grade consistency in bioactive compound concentrations. Advanced fingerprinting techniques now enable 98% batch-to-batch consistency in key alkaloid levels, addressing historical concerns about product variability. The development of nanoparticle delivery systems has enhanced bioavailability of water-insoluble active components from herbs like Ginkgo biloba, with some next-generation formulations demonstrating pharmacokinetic profiles comparable to synthetic drugs. These technological improvements are critical for market expansion, particularly in Western markets where standardized efficacy evidence is mandatory for regulatory approval and physician acceptance.
Regional Analysis: Cardiovascular and Cerebrovascular Chinese Patent Medicine Market
North America
The North American market for Chinese patent medicines in cardiovascular care demonstrates steady growth driven by increasing consumer interest in complementary therapies, though penetration remains modest compared to conventional pharmaceuticals. The United States represents nearly 90% of regional demand, with growing adoption among integrative medicine clinics and Asian-American communities. Key products like Danshen Dripping Pills and Ginkgo Biloba extracts are gaining FDA acceptance as dietary supplements, though therapeutic claims remain restricted. Market growth faces headwinds from physician skepticism and insurance coverage limitations, with fewer than 15% of private health plans routinely reimbursing for TCM cardiovascular treatments. Regulatory pathways increasingly focus on standardized extract formulations that meet Good Manufacturing Practice (GMP) standards, particularly for products entering through the FDA's Botanical Drug Development pathway.
Europe
Europe maintains the most developed Western market for Chinese cardiovascular patent medicines, supported by established regulatory frameworks like the Traditional Herbal Medicinal Products Directive. Germany and France lead regional adoption, where TCM products achieve medicine status with demonstrated safety and quality. The European market benefits from: strong research collaborations with Chinese institutions, growing geriatric populations seeking alternative therapies, and increasing physician training in integrative approaches. While cost containment pressures in national healthcare systems limit broad reimbursement, select products prescribed for secondary stroke prevention now receive partial coverage in several EU countries. The UK market shows particular growth potential as the NHS expands complementary therapy pilot programs in cardiovascular rehabilitation centers.
Asia-Pacific
Asia-Pacific dominates global demand, generating over 70% of total market revenue due to deep cultural acceptance and widespread healthcare integration of TCM. China's cardiovascular patent medicine sector benefits from: comprehensive insurance coverage (85% reimbursement for essential formulations), massive domestic manufacturing capacity, and government-mandated TCM integration in hospital protocols. While Japan and South Korea maintain more regulated markets favoring their traditional Kampo and Korean medicine systems, Southeast Asia demonstrates rapid market expansion with growing middle-class demand for preventive cardiovascular care. The region faces quality standardization challenges, with regulatory bodies implementing stricter testing requirements for heavy metals and active compound concentrations in exported products.
South America
South America represents an emerging market where Chinese cardiovascular patent medicines gain traction through cultural exchanges and traditional medicine diplomacy. Brazil and Argentina account for majority regional sales through: established Chinese immigrant communities, government-to-government healthcare partnerships, and growing middle-class interest in natural therapies. Market development faces challenges including inconsistent regulatory oversight, counterfeit product proliferation, and economic volatility impacting import capabilities. However, recent trade agreements facilitating direct TCM exports from China to major South American ports suggest improving market access. Local production remains limited, with over 90% of products imported directly from Chinese manufacturers.
Middle East & Africa
The Middle East and Africa show divergent market dynamics, with Gulf Cooperation Council countries demonstrating the strongest growth trajectory. The UAE and Saudi Arabia lead regional adoption through: government-supported integration of complementary medicine, high cardiovascular disease prevalence, and medical tourism initiatives featuring TCM therapies. Sub-Saharan Africa faces distribution and access challenges, though Chinese medical aid programs and diplomatic TCM clinics create grassroots awareness. Regulatory frameworks vary widely, with North African nations demonstrating more developed quality control systems compared to other regional markets. The expansion of Chinese pharmaceutical distributors into regional trade hubs like Dubai supports gradual market development across the broader region.
Report Scope
This market research report offers a holistic overview of global and regional markets for the forecast period 2025–2032. It presents accurate and actionable insights based on a blend of primary and secondary research.
Key Coverage Areas:
FREQUENTLY ASKED QUESTIONS:
What is the current market size of Global Cardiovascular and Cerebrovascular Chinese Patent Medicine Market?
-> Global Cardiovascular and Cerebrovascular Chinese Patent Medicine market was valued at USD 10.49 billion in 2024 and is projected to reach USD 18.76 billion by 2032.
Which key companies operate in Global Cardiovascular and Cerebrovascular Chinese Patent Medicine Market?
-> Key players include Beijing Tongrentang, Tasly Pharmaceutical, Shineway Pharmaceutical, Shaanxi Buchang Pharmaceutical, and Hutchison Whampoa Guangzhou Baiyunshan Chinese Medicine Company Limited.
What are the key growth drivers?
-> Key growth drivers include rising cardiovascular disease prevalence, government support for TCM, increasing healthcare expenditure, and growing acceptance of integrative medicine.
Which region dominates the market?
-> Asia-Pacific dominates the market, accounting for over 65% of global revenue, with China as the leading producer and consumer.
What are the emerging trends?
-> Emerging trends include modernization of traditional formulations, clinical validation efforts, digital health integration, and sustainable sourcing initiatives.
TABLE OF CONTENTS
1 Introduction to Research & Analysis Reports
1.1 Cardiovascular and Cerebrovascular Chinese Patent Medicine Market Definition
1.2 Market Segments
1.2.1 Segment by Type
1.2.2 Segment by Application
1.3 Global Cardiovascular and Cerebrovascular Chinese Patent Medicine Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global Cardiovascular and Cerebrovascular Chinese Patent Medicine Overall Market Size
2.1 Global Cardiovascular and Cerebrovascular Chinese Patent Medicine Market Size: 2024 VS 2032
2.2 Global Cardiovascular and Cerebrovascular Chinese Patent Medicine Market Size, Prospects & Forecasts: 2020-2032
2.3 Global Cardiovascular and Cerebrovascular Chinese Patent Medicine Sales: 2020-2032
3 Company Landscape
3.1 Top Cardiovascular and Cerebrovascular Chinese Patent Medicine Players in Global Market
3.2 Top Global Cardiovascular and Cerebrovascular Chinese Patent Medicine Companies Ranked by Revenue
3.3 Global Cardiovascular and Cerebrovascular Chinese Patent Medicine Revenue by Companies
3.4 Global Cardiovascular and Cerebrovascular Chinese Patent Medicine Sales by Companies
3.5 Global Cardiovascular and Cerebrovascular Chinese Patent Medicine Price by Manufacturer (2020-2025)
3.6 Top 3 and Top 5 Cardiovascular and Cerebrovascular Chinese Patent Medicine Companies in Global Market, by Revenue in 2024
3.7 Global Manufacturers Cardiovascular and Cerebrovascular Chinese Patent Medicine Product Type
3.8 Tier 1, Tier 2, and Tier 3 Cardiovascular and Cerebrovascular Chinese Patent Medicine Players in Global Market
3.8.1 List of Global Tier 1 Cardiovascular and Cerebrovascular Chinese Patent Medicine Companies
3.8.2 List of Global Tier 2 and Tier 3 Cardiovascular and Cerebrovascular Chinese Patent Medicine Companies
4 Sights by Product
4.1 Overview
4.1.1 Segment by Type - Global Cardiovascular and Cerebrovascular Chinese Patent Medicine Market Size Markets, 2024 & 2032
4.1.2 Oral
4.1.3 Injection
4.2 Segment by Type - Global Cardiovascular and Cerebrovascular Chinese Patent Medicine Revenue & Forecasts
4.2.1 Segment by Type - Global Cardiovascular and Cerebrovascular Chinese Patent Medicine Revenue, 2020-2025
4.2.2 Segment by Type - Global Cardiovascular and Cerebrovascular Chinese Patent Medicine Revenue, 2026-2032
4.2.3 Segment by Type - Global Cardiovascular and Cerebrovascular Chinese Patent Medicine Revenue Market Share, 2020-2032
4.3 Segment by Type - Global Cardiovascular and Cerebrovascular Chinese Patent Medicine Sales & Forecasts
4.3.1 Segment by Type - Global Cardiovascular and Cerebrovascular Chinese Patent Medicine Sales, 2020-2025
4.3.2 Segment by Type - Global Cardiovascular and Cerebrovascular Chinese Patent Medicine Sales, 2026-2032
4.3.3 Segment by Type - Global Cardiovascular and Cerebrovascular Chinese Patent Medicine Sales Market Share, 2020-2032
4.4 Segment by Type - Global Cardiovascular and Cerebrovascular Chinese Patent Medicine Price (Manufacturers Selling Prices), 2020-2032
5 Sights by Application
5.1 Overview
5.1.1 Segment by Application - Global Cardiovascular and Cerebrovascular Chinese Patent Medicine Market Size, 2024 & 2032
5.1.2 Hospital
5.1.3 Pharmacy
5.1.4 Clinic
5.2 Segment by Application - Global Cardiovascular and Cerebrovascular Chinese Patent Medicine Revenue & Forecasts
5.2.1 Segment by Application - Global Cardiovascular and Cerebrovascular Chinese Patent Medicine Revenue, 2020-2025
5.2.2 Segment by Application - Global Cardiovascular and Cerebrovascular Chinese Patent Medicine Revenue, 2026-2032
5.2.3 Segment by Application - Global Cardiovascular and Cerebrovascular Chinese Patent Medicine Revenue Market Share, 2020-2032
5.3 Segment by Application - Global Cardiovascular and Cerebrovascular Chinese Patent Medicine Sales & Forecasts
5.3.1 Segment by Application - Global Cardiovascular and Cerebrovascular Chinese Patent Medicine Sales, 2020-2025
5.3.2 Segment by Application - Global Cardiovascular and Cerebrovascular Chinese Patent Medicine Sales, 2026-2032
5.3.3 Segment by Application - Global Cardiovascular and Cerebrovascular Chinese Patent Medicine Sales Market Share, 2020-2032
5.4 Segment by Application - Global Cardiovascular and Cerebrovascular Chinese Patent Medicine Price (Manufacturers Selling Prices), 2020-2032
6 Sights by Region
6.1 By Region - Global Cardiovascular and Cerebrovascular Chinese Patent Medicine Market Size, 2024 & 2032
6.2 By Region - Global Cardiovascular and Cerebrovascular Chinese Patent Medicine Revenue & Forecasts
6.2.1 By Region - Global Cardiovascular and Cerebrovascular Chinese Patent Medicine Revenue, 2020-2025
6.2.2 By Region - Global Cardiovascular and Cerebrovascular Chinese Patent Medicine Revenue, 2026-2032
6.2.3 By Region - Global Cardiovascular and Cerebrovascular Chinese Patent Medicine Revenue Market Share, 2020-2032
6.3 By Region - Global Cardiovascular and Cerebrovascular Chinese Patent Medicine Sales & Forecasts
6.3.1 By Region - Global Cardiovascular and Cerebrovascular Chinese Patent Medicine Sales, 2020-2025
6.3.2 By Region - Global Cardiovascular and Cerebrovascular Chinese Patent Medicine Sales, 2026-2032
6.3.3 By Region - Global Cardiovascular and Cerebrovascular Chinese Patent Medicine Sales Market Share, 2020-2032
6.4 North America
6.4.1 By Country - North America Cardiovascular and Cerebrovascular Chinese Patent Medicine Revenue, 2020-2032
6.4.2 By Country - North America Cardiovascular and Cerebrovascular Chinese Patent Medicine Sales, 2020-2032
6.4.3 United States Cardiovascular and Cerebrovascular Chinese Patent Medicine Market Size, 2020-2032
6.4.4 Canada Cardiovascular and Cerebrovascular Chinese Patent Medicine Market Size, 2020-2032
6.4.5 Mexico Cardiovascular and Cerebrovascular Chinese Patent Medicine Market Size, 2020-2032
6.5 Europe
6.5.1 By Country - Europe Cardiovascular and Cerebrovascular Chinese Patent Medicine Revenue, 2020-2032
6.5.2 By Country - Europe Cardiovascular and Cerebrovascular Chinese Patent Medicine Sales, 2020-2032
6.5.3 Germany Cardiovascular and Cerebrovascular Chinese Patent Medicine Market Size, 2020-2032
6.5.4 France Cardiovascular and Cerebrovascular Chinese Patent Medicine Market Size, 2020-2032
6.5.5 U.K. Cardiovascular and Cerebrovascular Chinese Patent Medicine Market Size, 2020-2032
6.5.6 Italy Cardiovascular and Cerebrovascular Chinese Patent Medicine Market Size, 2020-2032
6.5.7 Russia Cardiovascular and Cerebrovascular Chinese Patent Medicine Market Size, 2020-2032
6.5.8 Nordic Countries Cardiovascular and Cerebrovascular Chinese Patent Medicine Market Size, 2020-2032
6.5.9 Benelux Cardiovascular and Cerebrovascular Chinese Patent Medicine Market Size, 2020-2032
6.6 Asia
6.6.1 By Region - Asia Cardiovascular and Cerebrovascular Chinese Patent Medicine Revenue, 2020-2032
6.6.2 By Region - Asia Cardiovascular and Cerebrovascular Chinese Patent Medicine Sales, 2020-2032
6.6.3 China Cardiovascular and Cerebrovascular Chinese Patent Medicine Market Size, 2020-2032
6.6.4 Japan Cardiovascular and Cerebrovascular Chinese Patent Medicine Market Size, 2020-2032
6.6.5 South Korea Cardiovascular and Cerebrovascular Chinese Patent Medicine Market Size, 2020-2032
6.6.6 Southeast Asia Cardiovascular and Cerebrovascular Chinese Patent Medicine Market Size, 2020-2032
6.6.7 India Cardiovascular and Cerebrovascular Chinese Patent Medicine Market Size, 2020-2032
6.7 South America
6.7.1 By Country - South America Cardiovascular and Cerebrovascular Chinese Patent Medicine Revenue, 2020-2032
6.7.2 By Country - South America Cardiovascular and Cerebrovascular Chinese Patent Medicine Sales, 2020-2032
6.7.3 Brazil Cardiovascular and Cerebrovascular Chinese Patent Medicine Market Size, 2020-2032
6.7.4 Argentina Cardiovascular and Cerebrovascular Chinese Patent Medicine Market Size, 2020-2032
6.8 Middle East & Africa
6.8.1 By Country - Middle East & Africa Cardiovascular and Cerebrovascular Chinese Patent Medicine Revenue, 2020-2032
6.8.2 By Country - Middle East & Africa Cardiovascular and Cerebrovascular Chinese Patent Medicine Sales, 2020-2032
6.8.3 Turkey Cardiovascular and Cerebrovascular Chinese Patent Medicine Market Size, 2020-2032
6.8.4 Israel Cardiovascular and Cerebrovascular Chinese Patent Medicine Market Size, 2020-2032
6.8.5 Saudi Arabia Cardiovascular and Cerebrovascular Chinese Patent Medicine Market Size, 2020-2032
6.8.6 UAE Cardiovascular and Cerebrovascular Chinese Patent Medicine Market Size, 2020-2032
7 Manufacturers & Brands Profiles
7.1 Beijing Tongrentang
7.1.1 Beijing Tongrentang Company Summary
7.1.2 Beijing Tongrentang Business Overview
7.1.3 Beijing Tongrentang Cardiovascular and Cerebrovascular Chinese Patent Medicine Major Product Offerings
7.1.4 Beijing Tongrentang Cardiovascular and Cerebrovascular Chinese Patent Medicine Sales and Revenue in Global (2020-2025)
7.1.5 Beijing Tongrentang Key News & Latest Developments
7.2 Tasly Pharmaceutical
7.2.1 Tasly Pharmaceutical Company Summary
7.2.2 Tasly Pharmaceutical Business Overview
7.2.3 Tasly Pharmaceutical Cardiovascular and Cerebrovascular Chinese Patent Medicine Major Product Offerings
7.2.4 Tasly Pharmaceutical Cardiovascular and Cerebrovascular Chinese Patent Medicine Sales and Revenue in Global (2020-2025)
7.2.5 Tasly Pharmaceutical Key News & Latest Developments
7.3 Shaanxi Buchang Pharmaceutical
7.3.1 Shaanxi Buchang Pharmaceutical Company Summary
7.3.2 Shaanxi Buchang Pharmaceutical Business Overview
7.3.3 Shaanxi Buchang Pharmaceutical Cardiovascular and Cerebrovascular Chinese Patent Medicine Major Product Offerings
7.3.4 Shaanxi Buchang Pharmaceutical Cardiovascular and Cerebrovascular Chinese Patent Medicine Sales and Revenue in Global (2020-2025)
7.3.5 Shaanxi Buchang Pharmaceutical Key News & Latest Developments
7.4 Hutchison Whampoa Guangzhou Baiyunshan Chinese Medicine Company Limited
7.4.1 Hutchison Whampoa Guangzhou Baiyunshan Chinese Medicine Company Limited Company Summary
7.4.2 Hutchison Whampoa Guangzhou Baiyunshan Chinese Medicine Company Limited Business Overview
7.4.3 Hutchison Whampoa Guangzhou Baiyunshan Chinese Medicine Company Limited Cardiovascular and Cerebrovascular Chinese Patent Medicine Major Product Offerings
7.4.4 Hutchison Whampoa Guangzhou Baiyunshan Chinese Medicine Company Limited Cardiovascular and Cerebrovascular Chinese Patent Medicine Sales and Revenue in Global (2020-2025)
7.4.5 Hutchison Whampoa Guangzhou Baiyunshan Chinese Medicine Company Limited Key News & Latest Developments
7.5 Dr.Willmar Schwabe GmbH & Co. KG
7.5.1 Dr.Willmar Schwabe GmbH & Co. KG Company Summary
7.5.2 Dr.Willmar Schwabe GmbH & Co. KG Business Overview
7.5.3 Dr.Willmar Schwabe GmbH & Co. KG Cardiovascular and Cerebrovascular Chinese Patent Medicine Major Product Offerings
7.5.4 Dr.Willmar Schwabe GmbH & Co. KG Cardiovascular and Cerebrovascular Chinese Patent Medicine Sales and Revenue in Global (2020-2025)
7.5.5 Dr.Willmar Schwabe GmbH & Co. KG Key News & Latest Developments
7.6 Shanxi Guang Yu Yuan Limited Company of Chinese Medicine
7.6.1 Shanxi Guang Yu Yuan Limited Company of Chinese Medicine Company Summary
7.6.2 Shanxi Guang Yu Yuan Limited Company of Chinese Medicine Business Overview
7.6.3 Shanxi Guang Yu Yuan Limited Company of Chinese Medicine Cardiovascular and Cerebrovascular Chinese Patent Medicine Major Product Offerings
7.6.4 Shanxi Guang Yu Yuan Limited Company of Chinese Medicine Cardiovascular and Cerebrovascular Chinese Patent Medicine Sales and Revenue in Global (2020-2025)
7.6.5 Shanxi Guang Yu Yuan Limited Company of Chinese Medicine Key News & Latest Developments
7.7 KPC Pharmaceuticals
7.7.1 KPC Pharmaceuticals Company Summary
7.7.2 KPC Pharmaceuticals Business Overview
7.7.3 KPC Pharmaceuticals Cardiovascular and Cerebrovascular Chinese Patent Medicine Major Product Offerings
7.7.4 KPC Pharmaceuticals Cardiovascular and Cerebrovascular Chinese Patent Medicine Sales and Revenue in Global (2020-2025)
7.7.5 KPC Pharmaceuticals Key News & Latest Developments
7.8 Sinopharm Zhijun
7.8.1 Sinopharm Zhijun Company Summary
7.8.2 Sinopharm Zhijun Business Overview
7.8.3 Sinopharm Zhijun Cardiovascular and Cerebrovascular Chinese Patent Medicine Major Product Offerings
7.8.4 Sinopharm Zhijun Cardiovascular and Cerebrovascular Chinese Patent Medicine Sales and Revenue in Global (2020-2025)
7.8.5 Sinopharm Zhijun Key News & Latest Developments
7.9 Shijiazhuang Yiling Pharmaceutical
7.9.1 Shijiazhuang Yiling Pharmaceutical Company Summary
7.9.2 Shijiazhuang Yiling Pharmaceutical Business Overview
7.9.3 Shijiazhuang Yiling Pharmaceutical Cardiovascular and Cerebrovascular Chinese Patent Medicine Major Product Offerings
7.9.4 Shijiazhuang Yiling Pharmaceutical Cardiovascular and Cerebrovascular Chinese Patent Medicine Sales and Revenue in Global (2020-2025)
7.9.5 Shijiazhuang Yiling Pharmaceutical Key News & Latest Developments
7.10 Shanxi Liye Pharmaceutical
7.10.1 Shanxi Liye Pharmaceutical Company Summary
7.10.2 Shanxi Liye Pharmaceutical Business Overview
7.10.3 Shanxi Liye Pharmaceutical Cardiovascular and Cerebrovascular Chinese Patent Medicine Major Product Offerings
7.10.4 Shanxi Liye Pharmaceutical Cardiovascular and Cerebrovascular Chinese Patent Medicine Sales and Revenue in Global (2020-2025)
7.10.5 Shanxi Liye Pharmaceutical Key News & Latest Developments
7.11 Shineway Pharmaceutical
7.11.1 Shineway Pharmaceutical Company Summary
7.11.2 Shineway Pharmaceutical Business Overview
7.11.3 Shineway Pharmaceutical Cardiovascular and Cerebrovascular Chinese Patent Medicine Major Product Offerings
7.11.4 Shineway Pharmaceutical Cardiovascular and Cerebrovascular Chinese Patent Medicine Sales and Revenue in Global (2020-2025)
7.11.5 Shineway Pharmaceutical Key News & Latest Developments
7.12 Guangzhou Baiyunshan Xingqun Pharmaceutical
7.12.1 Guangzhou Baiyunshan Xingqun Pharmaceutical Company Summary
7.12.2 Guangzhou Baiyunshan Xingqun Pharmaceutical Business Overview
7.12.3 Guangzhou Baiyunshan Xingqun Pharmaceutical Cardiovascular and Cerebrovascular Chinese Patent Medicine Major Product Offerings
7.12.4 Guangzhou Baiyunshan Xingqun Pharmaceutical Cardiovascular and Cerebrovascular Chinese Patent Medicine Sales and Revenue in Global (2020-2025)
7.12.5 Guangzhou Baiyunshan Xingqun Pharmaceutical Key News & Latest Developments
7.13 Jilin Xingxing Technology Pharmaceutical
7.13.1 Jilin Xingxing Technology Pharmaceutical Company Summary
7.13.2 Jilin Xingxing Technology Pharmaceutical Business Overview
7.13.3 Jilin Xingxing Technology Pharmaceutical Cardiovascular and Cerebrovascular Chinese Patent Medicine Major Product Offerings
7.13.4 Jilin Xingxing Technology Pharmaceutical Cardiovascular and Cerebrovascular Chinese Patent Medicine Sales and Revenue in Global (2020-2025)
7.13.5 Jilin Xingxing Technology Pharmaceutical Key News & Latest Developments
7.14 Sinopharm Zhonglian Pharmaceutical
7.14.1 Sinopharm Zhonglian Pharmaceutical Company Summary
7.14.2 Sinopharm Zhonglian Pharmaceutical Business Overview
7.14.3 Sinopharm Zhonglian Pharmaceutical Cardiovascular and Cerebrovascular Chinese Patent Medicine Major Product Offerings
7.14.4 Sinopharm Zhonglian Pharmaceutical Cardiovascular and Cerebrovascular Chinese Patent Medicine Sales and Revenue in Global (2020-2025)
7.14.5 Sinopharm Zhonglian Pharmaceutical Key News & Latest Developments
7.15 Beijing Peking University WBL Biotech
7.15.1 Beijing Peking University WBL Biotech Company Summary
7.15.2 Beijing Peking University WBL Biotech Business Overview
7.15.3 Beijing Peking University WBL Biotech Cardiovascular and Cerebrovascular Chinese Patent Medicine Major Product Offerings
7.15.4 Beijing Peking University WBL Biotech Cardiovascular and Cerebrovascular Chinese Patent Medicine Sales and Revenue in Global (2020-2025)
7.15.5 Beijing Peking University WBL Biotech Key News & Latest Developments
7.16 Yunnan Weihe Pharmaceuticals
7.16.1 Yunnan Weihe Pharmaceuticals Company Summary
7.16.2 Yunnan Weihe Pharmaceuticals Business Overview
7.16.3 Yunnan Weihe Pharmaceuticals Cardiovascular and Cerebrovascular Chinese Patent Medicine Major Product Offerings
7.16.4 Yunnan Weihe Pharmaceuticals Cardiovascular and Cerebrovascular Chinese Patent Medicine Sales and Revenue in Global (2020-2025)
7.16.5 Yunnan Weihe Pharmaceuticals Key News & Latest Developments
7.17 Guangxi Wuzhou Pharmaceuticals (GROUP)
7.17.1 Guangxi Wuzhou Pharmaceuticals (GROUP) Company Summary
7.17.2 Guangxi Wuzhou Pharmaceuticals (GROUP) Business Overview
7.17.3 Guangxi Wuzhou Pharmaceuticals (GROUP) Cardiovascular and Cerebrovascular Chinese Patent Medicine Major Product Offerings
7.17.4 Guangxi Wuzhou Pharmaceuticals (GROUP) Cardiovascular and Cerebrovascular Chinese Patent Medicine Sales and Revenue in Global (2020-2025)
7.17.5 Guangxi Wuzhou Pharmaceuticals (GROUP) Key News & Latest Developments
7.18 SPH NO.1 Biochemical & Pharmaceutical
7.18.1 SPH NO.1 Biochemical & Pharmaceutical Company Summary
7.18.2 SPH NO.1 Biochemical & Pharmaceutical Business Overview
7.18.3 SPH NO.1 Biochemical & Pharmaceutical Cardiovascular and Cerebrovascular Chinese Patent Medicine Major Product Offerings
7.18.4 SPH NO.1 Biochemical & Pharmaceutical Cardiovascular and Cerebrovascular Chinese Patent Medicine Sales and Revenue in Global (2020-2025)
7.18.5 SPH NO.1 Biochemical & Pharmaceutical Key News & Latest Developments
7.19 Chengdu Baiyu Pharmaceutical
7.19.1 Chengdu Baiyu Pharmaceutical Company Summary
7.19.2 Chengdu Baiyu Pharmaceutical Business Overview
7.19.3 Chengdu Baiyu Pharmaceutical Cardiovascular and Cerebrovascular Chinese Patent Medicine Major Product Offerings
7.19.4 Chengdu Baiyu Pharmaceutical Cardiovascular and Cerebrovascular Chinese Patent Medicine Sales and Revenue in Global (2020-2025)
7.19.5 Chengdu Baiyu Pharmaceutical Key News & Latest Developments
7.20 Shanghai Greenvalley Pharmaceutical
7.20.1 Shanghai Greenvalley Pharmaceutical Company Summary
7.20.2 Shanghai Greenvalley Pharmaceutical Business Overview
7.20.3 Shanghai Greenvalley Pharmaceutical Cardiovascular and Cerebrovascular Chinese Patent Medicine Major Product Offerings
7.20.4 Shanghai Greenvalley Pharmaceutical Cardiovascular and Cerebrovascular Chinese Patent Medicine Sales and Revenue in Global (2020-2025)
7.20.5 Shanghai Greenvalley Pharmaceutical Key News & Latest Developments
7.21 Shanghai Hutchison Pharmaceuticals
7.21.1 Shanghai Hutchison Pharmaceuticals Company Summary
7.21.2 Shanghai Hutchison Pharmaceuticals Business Overview
7.21.3 Shanghai Hutchison Pharmaceuticals Cardiovascular and Cerebrovascular Chinese Patent Medicine Major Product Offerings
7.21.4 Shanghai Hutchison Pharmaceuticals Cardiovascular and Cerebrovascular Chinese Patent Medicine Sales and Revenue in Global (2020-2025)
7.21.5 Shanghai Hutchison Pharmaceuticals Key News & Latest Developments
8 Global Cardiovascular and Cerebrovascular Chinese Patent Medicine Production Capacity, Analysis
8.1 Global Cardiovascular and Cerebrovascular Chinese Patent Medicine Production Capacity, 2020-2032
8.2 Cardiovascular and Cerebrovascular Chinese Patent Medicine Production Capacity of Key Manufacturers in Global Market
8.3 Global Cardiovascular and Cerebrovascular Chinese Patent Medicine Production by Region
9 Key Market Trends, Opportunity, Drivers and Restraints
9.1 Market Opportunities & Trends
9.2 Market Drivers
9.3 Market Restraints
10 Cardiovascular and Cerebrovascular Chinese Patent Medicine Supply Chain Analysis
10.1 Cardiovascular and Cerebrovascular Chinese Patent Medicine Industry Value Chain
10.2 Cardiovascular and Cerebrovascular Chinese Patent Medicine Upstream Market
10.3 Cardiovascular and Cerebrovascular Chinese Patent Medicine Downstream and Clients
10.4 Marketing Channels Analysis
10.4.1 Marketing Channels
10.4.2 Cardiovascular and Cerebrovascular Chinese Patent Medicine Distributors and Sales Agents in Global
11 Conclusion
12 Appendix
12.1 Note
12.2 Examples of Clients
12.3 Disclaimer
LIST OF TABLES & FIGURES
List of Tables
Table 1. Key Players of Cardiovascular and Cerebrovascular Chinese Patent Medicine in Global Market
Table 2. Top Cardiovascular and Cerebrovascular Chinese Patent Medicine Players in Global Market, Ranking by Revenue (2024)
Table 3. Global Cardiovascular and Cerebrovascular Chinese Patent Medicine Revenue by Companies, (US$, Mn), 2020-2025
Table 4. Global Cardiovascular and Cerebrovascular Chinese Patent Medicine Revenue Share by Companies, 2020-2025
Table 5. Global Cardiovascular and Cerebrovascular Chinese Patent Medicine Sales by Companies, (K Units), 2020-2025
Table 6. Global Cardiovascular and Cerebrovascular Chinese Patent Medicine Sales Share by Companies, 2020-2025
Table 7. Key Manufacturers Cardiovascular and Cerebrovascular Chinese Patent Medicine Price (2020-2025) & (US$/Unit)
Table 8. Global Manufacturers Cardiovascular and Cerebrovascular Chinese Patent Medicine Product Type
Table 9. List of Global Tier 1 Cardiovascular and Cerebrovascular Chinese Patent Medicine Companies, Revenue (US$, Mn) in 2024 and Market Share
Table 10. List of Global Tier 2 and Tier 3 Cardiovascular and Cerebrovascular Chinese Patent Medicine Companies, Revenue (US$, Mn) in 2024 and Market Share
Table 11. Segment by Type � Global Cardiovascular and Cerebrovascular Chinese Patent Medicine Revenue, (US$, Mn), 2024 & 2032
Table 12. Segment by Type - Global Cardiovascular and Cerebrovascular Chinese Patent Medicine Revenue (US$, Mn), 2020-2025
Table 13. Segment by Type - Global Cardiovascular and Cerebrovascular Chinese Patent Medicine Revenue (US$, Mn), 2026-2032
Table 14. Segment by Type - Global Cardiovascular and Cerebrovascular Chinese Patent Medicine Sales (K Units), 2020-2025
Table 15. Segment by Type - Global Cardiovascular and Cerebrovascular Chinese Patent Medicine Sales (K Units), 2026-2032
Table 16. Segment by Application � Global Cardiovascular and Cerebrovascular Chinese Patent Medicine Revenue, (US$, Mn), 2024 & 2032
Table 17. Segment by Application - Global Cardiovascular and Cerebrovascular Chinese Patent Medicine Revenue, (US$, Mn), 2020-2025
Table 18. Segment by Application - Global Cardiovascular and Cerebrovascular Chinese Patent Medicine Revenue, (US$, Mn), 2026-2032
Table 19. Segment by Application - Global Cardiovascular and Cerebrovascular Chinese Patent Medicine Sales, (K Units), 2020-2025
Table 20. Segment by Application - Global Cardiovascular and Cerebrovascular Chinese Patent Medicine Sales, (K Units), 2026-2032
Table 21. By Region � Global Cardiovascular and Cerebrovascular Chinese Patent Medicine Revenue, (US$, Mn), 2025-2032
Table 22. By Region - Global Cardiovascular and Cerebrovascular Chinese Patent Medicine Revenue, (US$, Mn), 2020-2025
Table 23. By Region - Global Cardiovascular and Cerebrovascular Chinese Patent Medicine Revenue, (US$, Mn), 2026-2032
Table 24. By Region - Global Cardiovascular and Cerebrovascular Chinese Patent Medicine Sales, (K Units), 2020-2025
Table 25. By Region - Global Cardiovascular and Cerebrovascular Chinese Patent Medicine Sales, (K Units), 2026-2032
Table 26. By Country - North America Cardiovascular and Cerebrovascular Chinese Patent Medicine Revenue, (US$, Mn), 2020-2025
Table 27. By Country - North America Cardiovascular and Cerebrovascular Chinese Patent Medicine Revenue, (US$, Mn), 2026-2032
Table 28. By Country - North America Cardiovascular and Cerebrovascular Chinese Patent Medicine Sales, (K Units), 2020-2025
Table 29. By Country - North America Cardiovascular and Cerebrovascular Chinese Patent Medicine Sales, (K Units), 2026-2032
Table 30. By Country - Europe Cardiovascular and Cerebrovascular Chinese Patent Medicine Revenue, (US$, Mn), 2020-2025
Table 31. By Country - Europe Cardiovascular and Cerebrovascular Chinese Patent Medicine Revenue, (US$, Mn), 2026-2032
Table 32. By Country - Europe Cardiovascular and Cerebrovascular Chinese Patent Medicine Sales, (K Units), 2020-2025
Table 33. By Country - Europe Cardiovascular and Cerebrovascular Chinese Patent Medicine Sales, (K Units), 2026-2032
Table 34. By Region - Asia Cardiovascular and Cerebrovascular Chinese Patent Medicine Revenue, (US$, Mn), 2020-2025
Table 35. By Region - Asia Cardiovascular and Cerebrovascular Chinese Patent Medicine Revenue, (US$, Mn), 2026-2032
Table 36. By Region - Asia Cardiovascular and Cerebrovascular Chinese Patent Medicine Sales, (K Units), 2020-2025
Table 37. By Region - Asia Cardiovascular and Cerebrovascular Chinese Patent Medicine Sales, (K Units), 2026-2032
Table 38. By Country - South America Cardiovascular and Cerebrovascular Chinese Patent Medicine Revenue, (US$, Mn), 2020-2025
Table 39. By Country - South America Cardiovascular and Cerebrovascular Chinese Patent Medicine Revenue, (US$, Mn), 2026-2032
Table 40. By Country - South America Cardiovascular and Cerebrovascular Chinese Patent Medicine Sales, (K Units), 2020-2025
Table 41. By Country - South America Cardiovascular and Cerebrovascular Chinese Patent Medicine Sales, (K Units), 2026-2032
Table 42. By Country - Middle East & Africa Cardiovascular and Cerebrovascular Chinese Patent Medicine Revenue, (US$, Mn), 2020-2025
Table 43. By Country - Middle East & Africa Cardiovascular and Cerebrovascular Chinese Patent Medicine Revenue, (US$, Mn), 2026-2032
Table 44. By Country - Middle East & Africa Cardiovascular and Cerebrovascular Chinese Patent Medicine Sales, (K Units), 2020-2025
Table 45. By Country - Middle East & Africa Cardiovascular and Cerebrovascular Chinese Patent Medicine Sales, (K Units), 2026-2032
Table 46. Beijing Tongrentang Company Summary
Table 47. Beijing Tongrentang Cardiovascular and Cerebrovascular Chinese Patent Medicine Product Offerings
Table 48. Beijing Tongrentang Cardiovascular and Cerebrovascular Chinese Patent Medicine Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) & (2020-2025)
Table 49. Beijing Tongrentang Key News & Latest Developments
Table 50. Tasly Pharmaceutical Company Summary
Table 51. Tasly Pharmaceutical Cardiovascular and Cerebrovascular Chinese Patent Medicine Product Offerings
Table 52. Tasly Pharmaceutical Cardiovascular and Cerebrovascular Chinese Patent Medicine Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) & (2020-2025)
Table 53. Tasly Pharmaceutical Key News & Latest Developments
Table 54. Shaanxi Buchang Pharmaceutical Company Summary
Table 55. Shaanxi Buchang Pharmaceutical Cardiovascular and Cerebrovascular Chinese Patent Medicine Product Offerings
Table 56. Shaanxi Buchang Pharmaceutical Cardiovascular and Cerebrovascular Chinese Patent Medicine Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) & (2020-2025)
Table 57. Shaanxi Buchang Pharmaceutical Key News & Latest Developments
Table 58. Hutchison Whampoa Guangzhou Baiyunshan Chinese Medicine Company Limited Company Summary
Table 59. Hutchison Whampoa Guangzhou Baiyunshan Chinese Medicine Company Limited Cardiovascular and Cerebrovascular Chinese Patent Medicine Product Offerings
Table 60. Hutchison Whampoa Guangzhou Baiyunshan Chinese Medicine Company Limited Cardiovascular and Cerebrovascular Chinese Patent Medicine Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) & (2020-2025)
Table 61. Hutchison Whampoa Guangzhou Baiyunshan Chinese Medicine Company Limited Key News & Latest Developments
Table 62. Dr.Willmar Schwabe GmbH & Co. KG Company Summary
Table 63. Dr.Willmar Schwabe GmbH & Co. KG Cardiovascular and Cerebrovascular Chinese Patent Medicine Product Offerings
Table 64. Dr.Willmar Schwabe GmbH & Co. KG Cardiovascular and Cerebrovascular Chinese Patent Medicine Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) & (2020-2025)
Table 65. Dr.Willmar Schwabe GmbH & Co. KG Key News & Latest Developments
Table 66. Shanxi Guang Yu Yuan Limited Company of Chinese Medicine Company Summary
Table 67. Shanxi Guang Yu Yuan Limited Company of Chinese Medicine Cardiovascular and Cerebrovascular Chinese Patent Medicine Product Offerings
Table 68. Shanxi Guang Yu Yuan Limited Company of Chinese Medicine Cardiovascular and Cerebrovascular Chinese Patent Medicine Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) & (2020-2025)
Table 69. Shanxi Guang Yu Yuan Limited Company of Chinese Medicine Key News & Latest Developments
Table 70. KPC Pharmaceuticals Company Summary
Table 71. KPC Pharmaceuticals Cardiovascular and Cerebrovascular Chinese Patent Medicine Product Offerings
Table 72. KPC Pharmaceuticals Cardiovascular and Cerebrovascular Chinese Patent Medicine Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) & (2020-2025)
Table 73. KPC Pharmaceuticals Key News & Latest Developments
Table 74. Sinopharm Zhijun Company Summary
Table 75. Sinopharm Zhijun Cardiovascular and Cerebrovascular Chinese Patent Medicine Product Offerings
Table 76. Sinopharm Zhijun Cardiovascular and Cerebrovascular Chinese Patent Medicine Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) & (2020-2025)
Table 77. Sinopharm Zhijun Key News & Latest Developments
Table 78. Shijiazhuang Yiling Pharmaceutical Company Summary
Table 79. Shijiazhuang Yiling Pharmaceutical Cardiovascular and Cerebrovascular Chinese Patent Medicine Product Offerings
Table 80. Shijiazhuang Yiling Pharmaceutical Cardiovascular and Cerebrovascular Chinese Patent Medicine Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) & (2020-2025)
Table 81. Shijiazhuang Yiling Pharmaceutical Key News & Latest Developments
Table 82. Shanxi Liye Pharmaceutical Company Summary
Table 83. Shanxi Liye Pharmaceutical Cardiovascular and Cerebrovascular Chinese Patent Medicine Product Offerings
Table 84. Shanxi Liye Pharmaceutical Cardiovascular and Cerebrovascular Chinese Patent Medicine Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) & (2020-2025)
Table 85. Shanxi Liye Pharmaceutical Key News & Latest Developments
Table 86. Shineway Pharmaceutical Company Summary
Table 87. Shineway Pharmaceutical Cardiovascular and Cerebrovascular Chinese Patent Medicine Product Offerings
Table 88. Shineway Pharmaceutical Cardiovascular and Cerebrovascular Chinese Patent Medicine Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) & (2020-2025)
Table 89. Shineway Pharmaceutical Key News & Latest Developments
Table 90. Guangzhou Baiyunshan Xingqun Pharmaceutical Company Summary
Table 91. Guangzhou Baiyunshan Xingqun Pharmaceutical Cardiovascular and Cerebrovascular Chinese Patent Medicine Product Offerings
Table 92. Guangzhou Baiyunshan Xingqun Pharmaceutical Cardiovascular and Cerebrovascular Chinese Patent Medicine Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) & (2020-2025)
Table 93. Guangzhou Baiyunshan Xingqun Pharmaceutical Key News & Latest Developments
Table 94. Jilin Xingxing Technology Pharmaceutical Company Summary
Table 95. Jilin Xingxing Technology Pharmaceutical Cardiovascular and Cerebrovascular Chinese Patent Medicine Product Offerings
Table 96. Jilin Xingxing Technology Pharmaceutical Cardiovascular and Cerebrovascular Chinese Patent Medicine Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) & (2020-2025)
Table 97. Jilin Xingxing Technology Pharmaceutical Key News & Latest Developments
Table 98. Sinopharm Zhonglian Pharmaceutical Company Summary
Table 99. Sinopharm Zhonglian Pharmaceutical Cardiovascular and Cerebrovascular Chinese Patent Medicine Product Offerings
Table 100. Sinopharm Zhonglian Pharmaceutical Cardiovascular and Cerebrovascular Chinese Patent Medicine Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) & (2020-2025)
Table 101. Sinopharm Zhonglian Pharmaceutical Key News & Latest Developments
Table 102. Beijing Peking University WBL Biotech Company Summary
Table 103. Beijing Peking University WBL Biotech Cardiovascular and Cerebrovascular Chinese Patent Medicine Product Offerings
Table 104. Beijing Peking University WBL Biotech Cardiovascular and Cerebrovascular Chinese Patent Medicine Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) & (2020-2025)
Table 105. Beijing Peking University WBL Biotech Key News & Latest Developments
Table 106. Yunnan Weihe Pharmaceuticals Company Summary
Table 107. Yunnan Weihe Pharmaceuticals Cardiovascular and Cerebrovascular Chinese Patent Medicine Product Offerings
Table 108. Yunnan Weihe Pharmaceuticals Cardiovascular and Cerebrovascular Chinese Patent Medicine Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) & (2020-2025)
Table 109. Yunnan Weihe Pharmaceuticals Key News & Latest Developments
Table 110. Guangxi Wuzhou Pharmaceuticals (GROUP) Company Summary
Table 111. Guangxi Wuzhou Pharmaceuticals (GROUP) Cardiovascular and Cerebrovascular Chinese Patent Medicine Product Offerings
Table 112. Guangxi Wuzhou Pharmaceuticals (GROUP) Cardiovascular and Cerebrovascular Chinese Patent Medicine Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) & (2020-2025)
Table 113. Guangxi Wuzhou Pharmaceuticals (GROUP) Key News & Latest Developments
Table 114. SPH NO.1 Biochemical & Pharmaceutical Company Summary
Table 115. SPH NO.1 Biochemical & Pharmaceutical Cardiovascular and Cerebrovascular Chinese Patent Medicine Product Offerings
Table 116. SPH NO.1 Biochemical & Pharmaceutical Cardiovascular and Cerebrovascular Chinese Patent Medicine Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) & (2020-2025)
Table 117. SPH NO.1 Biochemical & Pharmaceutical Key News & Latest Developments
Table 118. Chengdu Baiyu Pharmaceutical Company Summary
Table 119. Chengdu Baiyu Pharmaceutical Cardiovascular and Cerebrovascular Chinese Patent Medicine Product Offerings
Table 120. Chengdu Baiyu Pharmaceutical Cardiovascular and Cerebrovascular Chinese Patent Medicine Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) & (2020-2025)
Table 121. Chengdu Baiyu Pharmaceutical Key News & Latest Developments
Table 122. Shanghai Greenvalley Pharmaceutical Company Summary
Table 123. Shanghai Greenvalley Pharmaceutical Cardiovascular and Cerebrovascular Chinese Patent Medicine Product Offerings
Table 124. Shanghai Greenvalley Pharmaceutical Cardiovascular and Cerebrovascular Chinese Patent Medicine Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) & (2020-2025)
Table 125. Shanghai Greenvalley Pharmaceutical Key News & Latest Developments
Table 126. Shanghai Hutchison Pharmaceuticals Company Summary
Table 127. Shanghai Hutchison Pharmaceuticals Cardiovascular and Cerebrovascular Chinese Patent Medicine Product Offerings
Table 128. Shanghai Hutchison Pharmaceuticals Cardiovascular and Cerebrovascular Chinese Patent Medicine Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) & (2020-2025)
Table 129. Shanghai Hutchison Pharmaceuticals Key News & Latest Developments
Table 130. Cardiovascular and Cerebrovascular Chinese Patent Medicine Capacity of Key Manufacturers in Global Market, 2023-2025 (K Units)
Table 131. Global Cardiovascular and Cerebrovascular Chinese Patent Medicine Capacity Market Share of Key Manufacturers, 2023-2025
Table 132. Global Cardiovascular and Cerebrovascular Chinese Patent Medicine Production by Region, 2020-2025 (K Units)
Table 133. Global Cardiovascular and Cerebrovascular Chinese Patent Medicine Production by Region, 2026-2032 (K Units)
Table 134. Cardiovascular and Cerebrovascular Chinese Patent Medicine Market Opportunities & Trends in Global Market
Table 135. Cardiovascular and Cerebrovascular Chinese Patent Medicine Market Drivers in Global Market
Table 136. Cardiovascular and Cerebrovascular Chinese Patent Medicine Market Restraints in Global Market
Table 137. Cardiovascular and Cerebrovascular Chinese Patent Medicine Raw Materials
Table 138. Cardiovascular and Cerebrovascular Chinese Patent Medicine Raw Materials Suppliers in Global Market
Table 139. Typical Cardiovascular and Cerebrovascular Chinese Patent Medicine Downstream
Table 140. Cardiovascular and Cerebrovascular Chinese Patent Medicine Downstream Clients in Global Market
Table 141. Cardiovascular and Cerebrovascular Chinese Patent Medicine Distributors and Sales Agents in Global Market
List of Figures
Figure 1. Cardiovascular and Cerebrovascular Chinese Patent Medicine Product Picture
Figure 2. Cardiovascular and Cerebrovascular Chinese Patent Medicine Segment by Type in 2024
Figure 3. Cardiovascular and Cerebrovascular Chinese Patent Medicine Segment by Application in 2024
Figure 4. Global Cardiovascular and Cerebrovascular Chinese Patent Medicine Market Overview: 2024
Figure 5. Key Caveats
Figure 6. Global Cardiovascular and Cerebrovascular Chinese Patent Medicine Market Size: 2024 VS 2032 (US$, Mn)
Figure 7. Global Cardiovascular and Cerebrovascular Chinese Patent Medicine Revenue: 2020-2032 (US$, Mn)
Figure 8. Cardiovascular and Cerebrovascular Chinese Patent Medicine Sales in Global Market: 2020-2032 (K Units)
Figure 9. The Top 3 and 5 Players Market Share by Cardiovascular and Cerebrovascular Chinese Patent Medicine Revenue in 2024
Figure 10. Segment by Type � Global Cardiovascular and Cerebrovascular Chinese Patent Medicine Revenue, (US$, Mn), 2024 & 2032
Figure 11. Segment by Type - Global Cardiovascular and Cerebrovascular Chinese Patent Medicine Revenue Market Share, 2020-2032
Figure 12. Segment by Type - Global Cardiovascular and Cerebrovascular Chinese Patent Medicine Sales Market Share, 2020-2032
Figure 13. Segment by Type - Global Cardiovascular and Cerebrovascular Chinese Patent Medicine Price (US$/Unit), 2020-2032
Figure 14. Segment by Application � Global Cardiovascular and Cerebrovascular Chinese Patent Medicine Revenue, (US$, Mn), 2024 & 2032
Figure 15. Segment by Application - Global Cardiovascular and Cerebrovascular Chinese Patent Medicine Revenue Market Share, 2020-2032
Figure 16. Segment by Application - Global Cardiovascular and Cerebrovascular Chinese Patent Medicine Sales Market Share, 2020-2032
Figure 17. Segment by Application -Global Cardiovascular and Cerebrovascular Chinese Patent Medicine Price (US$/Unit), 2020-2032
Figure 18. By Region � Global Cardiovascular and Cerebrovascular Chinese Patent Medicine Revenue, (US$, Mn), 2025 & 2032
Figure 19. By Region - Global Cardiovascular and Cerebrovascular Chinese Patent Medicine Revenue Market Share, 2020 VS 2024 VS 2032
Figure 20. By Region - Global Cardiovascular and Cerebrovascular Chinese Patent Medicine Revenue Market Share, 2020-2032
Figure 21. By Region - Global Cardiovascular and Cerebrovascular Chinese Patent Medicine Sales Market Share, 2020-2032
Figure 22. By Country - North America Cardiovascular and Cerebrovascular Chinese Patent Medicine Revenue Market Share, 2020-2032
Figure 23. By Country - North America Cardiovascular and Cerebrovascular Chinese Patent Medicine Sales Market Share, 2020-2032
Figure 24. United States Cardiovascular and Cerebrovascular Chinese Patent Medicine Revenue, (US$, Mn), 2020-2032
Figure 25. Canada Cardiovascular and Cerebrovascular Chinese Patent Medicine Revenue, (US$, Mn), 2020-2032
Figure 26. Mexico Cardiovascular and Cerebrovascular Chinese Patent Medicine Revenue, (US$, Mn), 2020-2032
Figure 27. By Country - Europe Cardiovascular and Cerebrovascular Chinese Patent Medicine Revenue Market Share, 2020-2032
Figure 28. By Country - Europe Cardiovascular and Cerebrovascular Chinese Patent Medicine Sales Market Share, 2020-2032
Figure 29. Germany Cardiovascular and Cerebrovascular Chinese Patent Medicine Revenue, (US$, Mn), 2020-2032
Figure 30. France Cardiovascular and Cerebrovascular Chinese Patent Medicine Revenue, (US$, Mn), 2020-2032
Figure 31. U.K. Cardiovascular and Cerebrovascular Chinese Patent Medicine Revenue, (US$, Mn), 2020-2032
Figure 32. Italy Cardiovascular and Cerebrovascular Chinese Patent Medicine Revenue, (US$, Mn), 2020-2032
Figure 33. Russia Cardiovascular and Cerebrovascular Chinese Patent Medicine Revenue, (US$, Mn), 2020-2032
Figure 34. Nordic Countries Cardiovascular and Cerebrovascular Chinese Patent Medicine Revenue, (US$, Mn), 2020-2032
Figure 35. Benelux Cardiovascular and Cerebrovascular Chinese Patent Medicine Revenue, (US$, Mn), 2020-2032
Figure 36. By Region - Asia Cardiovascular and Cerebrovascular Chinese Patent Medicine Revenue Market Share, 2020-2032
Figure 37. By Region - Asia Cardiovascular and Cerebrovascular Chinese Patent Medicine Sales Market Share, 2020-2032
Figure 38. China Cardiovascular and Cerebrovascular Chinese Patent Medicine Revenue, (US$, Mn), 2020-2032
Figure 39. Japan Cardiovascular and Cerebrovascular Chinese Patent Medicine Revenue, (US$, Mn), 2020-2032
Figure 40. South Korea Cardiovascular and Cerebrovascular Chinese Patent Medicine Revenue, (US$, Mn), 2020-2032
Figure 41. Southeast Asia Cardiovascular and Cerebrovascular Chinese Patent Medicine Revenue, (US$, Mn), 2020-2032
Figure 42. India Cardiovascular and Cerebrovascular Chinese Patent Medicine Revenue, (US$, Mn), 2020-2032
Figure 43. By Country - South America Cardiovascular and Cerebrovascular Chinese Patent Medicine Revenue Market Share, 2020-2032
Figure 44. By Country - South America Cardiovascular and Cerebrovascular Chinese Patent Medicine Sales, Market Share, 2020-2032
Figure 45. Brazil Cardiovascular and Cerebrovascular Chinese Patent Medicine Revenue, (US$, Mn), 2020-2032
Figure 46. Argentina Cardiovascular and Cerebrovascular Chinese Patent Medicine Revenue, (US$, Mn), 2020-2032
Figure 47. By Country - Middle East & Africa Cardiovascular and Cerebrovascular Chinese Patent Medicine Revenue, Market Share, 2020-2032
Figure 48. By Country - Middle East & Africa Cardiovascular and Cerebrovascular Chinese Patent Medicine Sales, Market Share, 2020-2032
Figure 49. Turkey Cardiovascular and Cerebrovascular Chinese Patent Medicine Revenue, (US$, Mn), 2020-2032
Figure 50. Israel Cardiovascular and Cerebrovascular Chinese Patent Medicine Revenue, (US$, Mn), 2020-2032
Figure 51. Saudi Arabia Cardiovascular and Cerebrovascular Chinese Patent Medicine Revenue, (US$, Mn), 2020-2032
Figure 52. UAE Cardiovascular and Cerebrovascular Chinese Patent Medicine Revenue, (US$, Mn), 2020-2032
Figure 53. Global Cardiovascular and Cerebrovascular Chinese Patent Medicine Production Capacity (K Units), 2020-2032
Figure 54. The Percentage of Production Cardiovascular and Cerebrovascular Chinese Patent Medicine by Region, 2024 VS 2032
Figure 55. Cardiovascular and Cerebrovascular Chinese Patent Medicine Industry Value Chain
Figure 56. Marketing Channels
